Patent application number | Description | Published |
20090144077 | METHOD AND SYSTEM FOR DETERMINING EXPOSURES PRESENTED BY AN ORCHESTRATED PROCESS - The present invention provides a system and method to dynamically identify, assemble, or otherwise simulate the availability of resources for an orchestrated service or application, thereby allowing for strategic changes in scheduling, purchasing, hiring, and the like to ensure that the resources needed to deliver the desired outcome during a particular time period are present. In particular, the system includes an orchestration module storing a plurality of resource parameters, correlating a predetermined criterion for one or more resources with an event, and simulating the event, where the simulation includes comparing the stored plurality of parameters with the predetermined criterion. The system further determines whether the stored plurality of parameters satisfy the predetermined criterion, and may store the determination for subsequent evaluation. | 06-04-2009 |
20110052539 | ONCOLYTIC RHABDOVIRUS - Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo. | 03-03-2011 |
20120134963 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY - Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided. | 05-31-2012 |
20140162342 | METHODS AND COMPOSITIONS FOR PRODUCTION OF VACCINA VIRUS - Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus. | 06-12-2014 |
20140193458 | METHOD OF VACCINATION COMPRISING A HISTONE DEACETYLASE INHIBITOR - A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity. | 07-10-2014 |
20150037355 | GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS - The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor. | 02-05-2015 |
Patent application number | Description | Published |
20090317362 | USE OF MYXOMA VIRUS FOR THE THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRAL INFECTION - The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer. | 12-24-2009 |
20100272687 | MUTANT VIRUSES AND USES THEREOF - The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells. | 10-28-2010 |
20110044937 | STAGED IMMUNE-RESPONSE MODULATION IN ONCOLYTIC THERAPY - The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response. | 02-24-2011 |
20110206640 | ENGINEERED SYNERGISTIC ONCOLYTIC VIRAL SYMBIOSIS - In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host. | 08-25-2011 |
20120275999 | ONCOLYTIC RHABDOVIRUS - Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo. | 11-01-2012 |
Patent application number | Description | Published |
20110280130 | Systems and Methods for Network Congestion Management Using Radio Access Network Congestion Indicators - Systems and methods for managing communications network congestion are provided. In an embodiment, the system includes a radio access network (RAN) interface configured to receive RAN congestion indicators, a congestion correlator module configured to correlate RAN congestion indicators to service congestion indicators, a database comprising a set of congestion based policy rules, a policy controller module configured to apply the congestion-based policy rules to achieve a policy decision, and a policy enforcement control point interface configured to transmit network control instructions to enforce the policy decisions. In another embodiment of the invention, a method is provided for managing communications network congestion, that includes receiving one or more radio access network (RAN) congestion indicators, correlating the one or more RAN congestion indicators to one or more service congestion indicators, applying a congestion-based policy rule based on service congestion indicators to generate a policy decision, and implementing the policy decision. | 11-17-2011 |
20120026879 | Systems and Methods For Network Congestion Management Using Radio Access Network Congestion Indicators - Systems and methods for managing communications network congestion are provided. In an embodiment, the system includes a radio access network (RAN) interface configured to receive RAN congestion indicators, a congestion correlator module configured to correlate RAN congestion indicators to service congestion indicators, a database comprising a set of congestion based policy rules, a policy controller module configured to apply the congestion-based policy rules to achieve a policy decision, and a policy enforcement control point interface configured to transmit network control instructions to enforce the policy decisions. In another embodiment of the invention, a method is provided for managing communications network congestion, that includes receiving one or more radio access network (RAN) congestion indicators, correlating the one or more RAN congestion indicators to one or more service congestion indicators, applying a congestion-based policy rule based on service congestion indicators to generate a policy decision, and implementing the policy decision. | 02-02-2012 |